How Much Does Tesamorelin Cost? (2026)

Tesamorelin sits in an unusual position in the peptide pricing landscape: it is actually FDA-approved. The brand-name formulation, now sold as Egrifta WR, completed rigorous Phase 3 clinical trials and received FDA approval in 2010 for a specific indication — excess abdominal fat in adults with HIV-associated lipodystrophy. That approval creates a pricing structure that looks nothing like what you see with unapproved peptides like BPC-157 or sermorelin.

The result is one of the most extreme price gaps in the injectable peptide market. Brand-name Egrifta WR can cost $3,000 to $10,000 or more per month at retail — priced as the specialty pharmaceutical it is. Compounded tesamorelin, available through telehealth clinics for off-label use, runs $150 to $700 monthly. Gray-market research vials are cheaper still at $36 to $79, but carry the label "not for human use" and none of the regulatory safeguards of either licensed pathway.

This guide breaks down every price tier, explains what the FDA's 2020 reclassification of tesamorelin means for compounding availability, covers insurance coverage rules, and details the patient assistance programs that can dramatically reduce the brand-name cost for qualifying patients.

Three pricing tiers, three very different products

Understanding tesamorelin pricing requires understanding that you are not comparing cheaper and more expensive versions of the same thing. You are comparing three distinct market structures, each with different legal status, quality standards, and oversight levels.

The first is the brand-name pathway: Egrifta WR, made by Theratechnologies, approved by the FDA, distributed through specialty pharmacies with physician oversight and insurance coverage for the approved indication. The second is the compounded pathway: licensed telehealth clinics prescribing the same active peptide, dispensed through state-licensed compounding pharmacies, available in cash for off-label use — with regulatory complications specific to tesamorelin that do not apply to most other compounded peptides. The third is the gray market: online vendors selling tesamorelin labeled "for research use only," requiring no prescription, providing no guaranteed quality testing, and carrying no physician oversight.

Tesamorelin price comparison by source

Source	Estimated monthly cost	Prescription required	Physician oversight	Independent quality testing	Insurance eligible
Brand Egrifta WR (specialty pharmacy)	$3,000–$10,000+	Yes	Yes	Yes (FDA-approved)	Yes — HIV lipodystrophy only
Brand Egrifta WR with Thera Patient Support	$0–$50 (qualifying patients)	Yes	Yes	Yes (FDA-approved)	Required for program eligibility
Compounded tesamorelin (licensed telehealth)	$150–$700	Yes	Yes	Pharmacy-dependent	No
Gray-market research vials (no prescription)	$36–$79 per vial	No	No	Not typically verified	No

Brand-name Egrifta WR: what the retail price reflects

In March 2025, the FDA approved Egrifta WR — the current formulation of tesamorelin made by Theratechnologies — as a supplemental biologics license application. Egrifta WR replaced the earlier Egrifta SV formulation. The new formulation requires only weekly reconstitution rather than daily mixing, which is the primary practical improvement for patients who need it for the approved HIV lipodystrophy indication. The product is patent-protected in the United States through 2033.

At retail, without insurance, Egrifta WR costs approximately $3,000 to $10,000 or more per month depending on the specialty pharmacy and the patient's specific supply needs. This price reflects the economics of specialty pharmaceutical development: the pivotal Phase 3 clinical trials that earned FDA approval enrolled more than 800 patients across two major studies, and those development costs get amortized across a relatively narrow patient population. The approved indication — HIV-associated lipodystrophy — affects a specific subset of adults living with HIV, not the general population seeking fat loss or body composition changes.

Egrifta WR is distributed through specialty pharmacy networks, including Accredo and AnovoRx. It is not available through general retail or mail-order pharmacies. Patients prescribed it for the approved indication typically require prior authorization from their insurer before dispensing begins.

The Thera Patient Support program: brand drug for $0–$50

For patients who meet eligibility criteria, the price gap between brand and compounded tesamorelin largely disappears. Theratechnologies operates the Thera Patient Support program (reachable at 1-833-238-4372), which can reduce out-of-pocket cost for commercially insured qualifying patients to as little as $0 to $50 per month for Egrifta WR.

Eligibility requires commercial insurance coverage — meaning insurance is already paying for the drug — combined with meeting the program's income or coverage criteria. Patients with HIV-associated lipodystrophy who have insurance should contact this program and their specialty pharmacy before accepting what appear to be prohibitive retail costs. The assistance program fundamentally changes the cost calculation for patients who qualify for the approved indication.

Medicare and Medicaid patients face different rules. Federal anti-kickback regulations limit manufacturer assistance programs for government insurance beneficiaries, so the Thera Patient Support program may not apply. Medicare Part D coverage for Egrifta WR, where it exists, follows standard specialty drug cost-share rules, which can still result in significant out-of-pocket costs without additional programs.

Compounded tesamorelin through licensed telehealth: $150–$700 monthly

For the majority of people seeking tesamorelin for off-label purposes — visceral fat reduction, body composition, or general growth hormone optimization — the compounded telehealth pathway is the practical route. The branded product is priced for its approved indication and is not practically available to the general population at retail prices. Compounding pharmacies can prepare the same active peptide at far lower cost through a cash-pay, direct-to-patient model.

Compounded tesamorelin through licensed telehealth clinics typically runs:

• Initial telehealth consultation: $100 to $200 for the intake evaluation and prescription
• Compounded peptide (monthly supply): $150 to $600 depending on the pharmacy, the vial concentration, and volume ordered
• Injection supplies: Syringes, alcohol swabs, and bacteriostatic water add approximately $15 to $30 monthly
• Follow-up visits: Typically $75 to $150, usually scheduled quarterly or at protocol milestones
• Lab work (IGF-1 and glucose monitoring): $100 to $300 when ordered by the prescribing physician, billed separately

Total first-month costs for a supervised compounded protocol typically run $300 to $900. Ongoing monthly costs after the initial evaluation settle into the $150 to $700 range depending on which telehealth platform and pharmacy are involved.

Some platforms bundle consultation, peptide, and supplies into a single monthly fee. Others itemize each component separately. Getting an all-in monthly cost estimate before committing to any program is the only way to make an accurate comparison across providers.

The regulatory complication unique to tesamorelin

Most peptides discussed on this site exist in a straightforward regulatory gray zone: they are not FDA-approved, not on the 503A authorized bulk drug substances list, and vendors sell them as "research use only" products. Tesamorelin is different, and more complicated.

In March 2020, the FDA reclassified tesamorelin as a biologic under the Biologics Price Competition and Innovation Act (BPCIA). That reclassification created a specific problem for compounding: the exemptions that allow licensed 503A pharmacies to compound conventional drugs do not extend to biologics in the same way. Tesamorelin is technically ineligible for the standard 503A compounding pathway that applies to unapproved peptides like sermorelin or ipamorelin.

Despite this, compounded tesamorelin remains widely available through telehealth platforms and compounding pharmacies. This is a legal gray zone created by the mismatch between the reclassification and existing compounding infrastructure. The FDA's enforcement priorities in this specific area have not been publicly established in the same way they were for peptides like BPC-157.

For patients considering compounded tesamorelin, this regulatory situation is worth understanding before committing. Confirm in writing with any prescribing physician and pharmacy that they are aware of the biologic reclassification and operating under current legal guidance. This is an area where the legal landscape can shift, and a patient who built their protocol around compounded access should have that conversation explicitly rather than assuming continued availability.¹

Gray-market research vials: $36–$79

Online vendors sell tesamorelin labeled "for research use only" at prices between $36 and $79 per vial, with no prescription required and no physician involved. These products represent the cheapest entry price but come without the quality controls, sterility verification, or medical oversight that characterize either the brand or compounded clinical pathways.

Dr. Pieter Cohen, Associate Professor of Medicine at Harvard Medical School, addressed the core problem with online-marketed peptide products directly:

"When you're talking about peptides being promoted online, those health claims have not been vetted by any expert group, the FDA, or anyone else. The health claims are divorced from data." — Dr. Pieter Cohen, Harvard Medical School³

That concern applies with particular force to gray-market tesamorelin. Unlike BPC-157 or CJC-1295 — which have no approved counterpart — tesamorelin does have a well-characterized brand-name product with extensive clinical trial data. Any vendor operating outside that regulatory framework is selling a product with none of those quality guarantees at a fraction of the brand price, for reasons that reflect what has been removed from the supply chain, not a more efficient alternative.

Sterility testing, purity verification by independent HPLC analysis, cold-chain shipping, and physician oversight are all absent from gray-market transactions. The cost saving is real. So is what that cost saving represents.

Insurance coverage: the rules

Tesamorelin is the only peptide discussed on this site for which insurance coverage exists — and it is highly conditional. The rules follow the FDA approval exactly:

• FDA-approved indication (HIV-associated lipodystrophy): Commercial insurance, Medicare, and Medicaid will typically cover brand-name Egrifta WR after prior authorization. The prescribing physician must document HIV diagnosis, evidence of excess abdominal adiposity from lipodystrophy, and meeting of coverage criteria. Prior authorization is required — coverage is not automatic.
• Off-label use (general fat loss, body composition, anti-aging): Insurance will not cover tesamorelin for these purposes, regardless of channel. Denials are consistent and nearly universal for off-label indications.
• Compounded tesamorelin: Not covered by insurance through any channel or for any indication.

Health Savings Accounts and Flexible Spending Accounts may be usable for compounded tesamorelin costs when a licensed physician prescribes it for a qualifying medical condition. This depends on individual plan rules and documentation. Confirm with your plan administrator before assuming HSA or FSA eligibility.

What the Phase 3 trial data established — and what it didn't

Understanding what tesamorelin's price is buying requires understanding what the clinical evidence actually established. Two pivotal Phase 3 randomized controlled trials enrolled more than 800 HIV-positive adults and demonstrated statistically significant reductions in visceral adipose tissue compared to placebo at 26 weeks — the evidence base that earned FDA approval and drove the development of the brand-name product now priced as a specialty pharmaceutical.⁴

What the trials also established, and what the FDA prescribing information documents: in clinical trial populations, 47 percent of patients receiving tesamorelin developed IGF-1 levels above 2 standard deviations above the mean by week 26. Elevated IGF-1 requires monitoring. The trials also documented increased glucose intolerance and injection site reactions in a meaningful proportion of participants. These findings are what make the physician monitoring component of a licensed protocol clinically relevant, not just a billing opportunity.

The clinical evidence base applies directly to HIV-associated lipodystrophy. Off-label use for general fat loss or body composition rests on extrapolation from those trials, not independent Phase 3 data for those uses. That distinction matters for how to weigh the cost-to-evidence ratio of any compounded protocol outside the approved indication.²

The long-term cost calculation

Patients comparing tesamorelin options frequently focus on monthly costs without accounting for the most important clinical finding from the trials: the visceral fat reductions observed in clinical studies do not persist after discontinuation. Visceral adipose tissue tends to return toward pre-treatment levels once tesamorelin is stopped. This makes tesamorelin an ongoing commitment rather than a finite course, which changes the total cost calculation significantly.

At $400 monthly for a supervised compounded protocol — a mid-range estimate for the cash-pay telehealth channel:

• 6 months: $2,400 plus initial consultation fees
• 12 months: $4,800 plus quarterly follow-up visits
• 2 years of ongoing use: $9,600 or more

At branded Egrifta WR retail prices for an off-label patient without insurance or assistance program access, the same 12-month period would cost $36,000 to $120,000 or more — a practical impossibility for most patients, which is exactly why the compounded channel exists at all.

For patients with HIV-associated lipodystrophy who qualify for the brand and the Thera Patient Support program, the long-term math reverses entirely: $0 to $50 monthly for the FDA-approved product with full clinical oversight, versus $4,800 annually out of pocket for the compounded alternative.

How tesamorelin cost compares to alternatives

Patients exploring tesamorelin for visceral fat reduction are often evaluating it against other options. For context:

• Compounded sermorelin: $100 to $300 monthly — a related growth hormone-releasing hormone analog with less clinical evidence and no FDA approval; typically lower cost than tesamorelin
• GLP-1 medications (compounded semaglutide or tirzepatide): $99 to $349 monthly at current telehealth pricing — different mechanism, typically larger total weight loss effect, though without tesamorelin's specificity for visceral versus subcutaneous fat
• CJC-1295/Ipamorelin: $200 to $500 monthly through supervised programs — common combination used for growth hormone optimization; similar price range to tesamorelin but different regulatory situation and evidence base
• Bariatric surgery: $10,000 to $25,000 or more out-of-pocket; largest total effect on weight; partially covered by insurance with qualifying criteria

Tesamorelin sits at the higher end of the compounded peptide price range, which reflects both the molecule's complexity and its stronger clinical evidence base compared to unapproved alternatives. Whether that premium is justified depends on the specific goal. For the approved HIV lipodystrophy indication with insurance, it competes favorably on cost with almost every alternative. For off-label use without insurance, the long-term monthly outlay is a meaningful commitment.

Questions to ask before committing to any tesamorelin program

• Is the pharmacy a licensed 503A facility, and are they aware of the biologic reclassification? Given tesamorelin's 2020 BPCIA reclassification, any pharmacy offering compounded tesamorelin should be able to explain their legal basis for doing so. If they cannot, that is a flag.
• What is the all-in monthly cost — consultation, peptide, supplies, labs, and follow-up? Low base prices that grow with separately billed components misrepresent the actual commitment. Get itemized estimates.
• Can you provide a batch-specific certificate of analysis from an independent laboratory? Reputable compounding pharmacies test each production batch for purity and sterility. If a pharmacy cannot provide a CoA from a genuinely independent lab, that is a quality concern.
• What IGF-1 and glucose monitoring does the protocol include? Given the rates of IGF-1 elevation and glucose intolerance documented in clinical trials, a program without built-in monitoring is not providing the full clinical service a compounded protocol at this price should include.
• For HIV patients: have you contacted the Thera Patient Support program? Patients with the approved indication who have commercial insurance should contact 1-833-238-4372 before defaulting to compounded alternatives. The assistance program may change the cost picture entirely.